Omecamtiv mecarbil is a novel cardiac myosin activator that is being studied for its potential in the treatment of heart failure. It works by increasing the contractility of the heart muscle, leading to improved cardiac output and function. Omecamtiv mecarbil has been shown to improve symptoms and exercise tolerance in patients with heart failure in early clinical trials. Further research is ongoing to determine its long-term safety and efficacy in a larger population of patients with heart failure.